Who is treated using restrictive behavioral procedures? A population perspective.

Nangle et al. (1993) looked at every person with intellectual disability served by one state. They counted how many had timeout on their plan and how many took psychoactive drugs.

The team pulled records for 31,000 people. They noted age, IQ level, living place, and top problem behavior.

Drugs won by a mile. Timeout was written into far fewer plans than pills for destructive behavior.

Lower IQ, younger age, living in a large facility, and showing self-injury all raised the chance a person had either restriction.

Klein et al. (2024) show the gap never closed. In British Columbia, one in three youth with IDD now take two or more drug classes at once—polypharmacy is the new normal.

Scheifes et al. (2013) echo the same picture in kids: almost 30 % of institutionalized children with mild ID already had a psychotropic script two decades later.

Nøttestad et al. (2003) add a twist. After people moved from institutions to group homes, neuroleptic use stayed flat. Place changed, numbers did not.

White et al. (1990) give a behavioral footnote. Their experiment found timeout can work, but only in leisure settings. The 1993 survey shows it is still rarely chosen, so the under-use is not because timeout fails—it is just overlooked.

If you write behavior plans, check the med list first. High drug loads can mimic or magnify problem behavior, so pair your functional assessment with a medication review. When data show a behavior is context-specific, try timeout in low-demand settings before adding another pill. Finally, schedule annual polypharmacy audits—Klein et al. (2024) prove they are now essential.